人民财讯1月14日电，一品红（300723）1月14日发布业绩预告，预计2025年净利润亏损3.13亿元—4.42 亿元，上年同期亏损5.4亿元。报告期，公司产品销售及毛利率水平有一定程度下降，加上公司广东瑞 石创新原料药生产基地投入使用导致折旧摊销增加及研发持续投入，影响了公司经营业绩。 ...

（文章来源：证券日报） 证券日报网讯 1月14日，东亚药业发布公告称，公司预计2025年度归属于上市公司股东的净利润为负 值，2025年度经营业绩将出现亏损。 ...

智通财经APP讯，联环药业(600513.SH)发布公告，公司财务部门经初步测算，预计公司2025年度归属 于上市公司股东的净利润为负值，2025年度经营业绩将出现亏损。 ...

证券日报网讯 1月14日，宏源药业在互动平台回答投资者提问时表示，公司密切关注各产品市场变动情 况，并及时调整营销策略。公司境内、外具体营销情况请关注公司后续定期报告。 （文章来源：证券日报） ...

Group 1: Small Nucleic Acid Business - The company's small nucleic acid business primarily includes phosphoramidite monomers and GalNAc delivery systems, with the capability to provide modified monomer processes to meet diverse customer needs [2][3] - Pricing for small nucleic acid monomers varies based on customer requirements, including different segments, quantities, and stages [3] - The company began its small nucleic acid business layout in 2024, driven by overseas agency promotion and technical cooperation [3] Group 2: Supply Chain and Production Capacity - MNC suppliers generally do not change key material suppliers easily due to the need for global registration and product process validation [3] - The company's production capacity is expected to meet the demands of small nucleic acid business as fundraising projects gradually release capacity [3] Group 3: Stem Cell Projects - The company has made progress in its cell therapy projects, including the completion of GMP facility design, installation, and validation for heart and brain infarction projects [3] - Technical transfers for umbilical cord mesenchymal stem cells have been completed, establishing seed, master, and working cell banks, along with method development and validation for analysis [3] Group 4: Investor Relations Activity - The investor relations activity took place on January 14, 2026, from 10:30 to 11:30 in the company meeting room, involving various investment firms [2] - The activity did not involve the disclosure of any undisclosed significant information [3]

格隆汇1月14日丨联环药业(600513.SH)公布，公司于近日收到交易商协会出具的《接受注册通知书》 （中市协注〔2026〕MTN2号），决定接受公司科技创新债券注册。现就有关事项公告如下： 一、公司本次注册基础品种为中期票据，注册金额为5亿元，注册额度自本通知书落款之日起2年内有 效，由南京银行股份有限公司和江苏银行股份有限公司联席主承销。二、公司在注册有效期内可分期发 行科技创新债券，接受注册后如需备案发行，应事前先向交易商协会备案。公司应按照有权机构决议及 相关管理要求，进行发行管理。发行完成后，公司应通过交易商协会认可的途径披露发行结果。 ...

一、公司本次注册基础品种为中期票据，注册金额为5亿元，注册额度自本通知书落款之日起2年内有 效，由南京银行股份有限公司和江苏银行股份有限公司联席主承销。二、公司在注册有效期内可分期发 行科技创新债券，接受注册后如需备案发行，应事前先向交易商协会备案。公司应按照有权机构决议及 相关管理要求，进行发行管理。发行完成后，公司应通过交易商协会认可的途径披露发行结果。 格隆汇1月14日丨联环药业(600513.SH)公布，公司于近日收到交易商协会出具的《接受注册通知书》 （中市协注〔2026〕MTN2号），决定接受公司科技创新债券注册。现就有关事项公告如下： ...

东亚药业（605177）(605177.SH)发布公告，经公司财务部门初步测算，预计公司2025年度归属于上市 公司股东的净利润为负值，2025年度经营业绩将出现亏损。 ...

Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a significant overseas revenue share [2][3]. Company Overview - Shenzhen Hepalink was established in 1998 and has dual financing platforms (A+H shares) [2]. - The main business segments include heparin sodium raw materials, low molecular weight heparin products, and CDMO services, with revenue contributions of 63.06% from formulations, 18.59% from CDMO, and 16.05% from heparin products [7]. - As of September 30, 2025, the company reported a revenue of 4.194 billion yuan, a year-on-year increase of 3.09%, while net profit decreased by 29.04% to 554 million yuan [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The total market capitalization is 18.048 billion yuan, with a trading volume of 87.8751 million yuan and a turnover rate of 0.57% [1]. Shareholder Information - As of September 30, 2025, the number of shareholders increased to 27,000, with an average of 0 circulating shares per person [7]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 12.0093 million shares, an increase of 691,700 shares from the previous period [9]. Technical Analysis - The average trading cost of the stock is 11.62 yuan, with the current price approaching a resistance level of 12.37 yuan, indicating potential for upward movement if the resistance is broken [6].

风险提示：提及个股仅用于行业事件分析，不构成任何个股推荐或投资建议。指数等短期涨跌仅供 参考，不代表其未来表现，亦不构成对基金业绩的承诺或保证。观点可能随市场环境变化而调整，不构 成投资建议或承诺。提及基金风险收益特征各不相同，敬请投资者仔细阅读基金法律文件，充分了解产 品要素、风险等级及收益分配原则，选择与自身风险承受能力匹配的产品，谨慎投资。 每日经济新闻 （责任编辑：董萍萍 ） 1月14日，创新药ETF国泰（517110）涨超1.4%，化学CDMO优势与生物领域竞争格局引关注。 国信证券指出，医药生物行业在化学制药领域，中国CXO企业在人才红利、化学能力、合规产 能、知识产权保护方面具有综合优势，欧洲地区生物制药产能建设周期较长，印度企业在知识产权保护 力度、高标准合规产能供给稳定性等方面仍存在明显短板，中国企业在化学CDMO领域的核心行业地位 5年内具备较强的不可替代性；生物领域，行业β明显，韩国、日本等国的生物药CDMO企业呈现出相 较于国内生物药CDMO企业更高的收入增速，中欧美日韩同台竞技，但在XDC的CRDMO领域，国内龙 头药明合联的全球市占率持续提升。长期维度需观察两大因素影响：一是"生物 ...